Nippon Kayaku Kabushiki Kaisha

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Nobuyoshi Shimada

Seiichi Saito

Shigeru Hasegawa

Hiroo Hoshino

Akio Fujii

Hamao Umezawa

Takashi Harada

Masayuki Kitagawa

Tomohisa Takita

Takayuki Tomizawa

Yukihiro Nishiyama

Tomio Takeuchi

Katsutoshi Takahashi

Kenichi Matsubara

Takemitsu Nagahata

Jun-ichi Seki

Masa Hamada

Hiroshi Naganawa

Masanori Yamazaki

Takaaki Nishikiori

Kiyonobu Hirose

Takashi Kurokawa

Akira Masuda

Masaaki Ishizuka

Takumi Yamashita

Kuniki Kato

Takumi Yamshita

Takako Tsuchiya

Noriyuki Yamashita

Kyoichi Shibuya

Kaoru Matsuo

It was found that 2-halogeno-oxetanocin A and 4'-phosphate thereof represented by the following general formula (1): ##STR1## wherein X represents a halogen atom and R represents a hydrogen atom or a phosphoric acid residue ##STR2## or salts thereof exhibit a strong antiviral activity and are useful as an active ingredient of therapeutic drug for viral diseases. Further, it was also found that the compounds of this invention are characterized in that they are not inactivated by adenosine deaminase widely present in living bodies and exhibit a high residual activity.

2-halogeno-oxetanocin A and phosphoric ester thereof

This invention relates to novel oxetanocins represented by the following general formula (I): ##STR1## wherein R represents a group represented by ##STR2## and their pharmacologically acceptable salts which have antiviral activities.

Oxetanocins

The present invention relates to phosphoric acid esters of oxetanocins having an antiviral activity which are represented by general formula (I): ##STR1## wherein R.sub.1 represents a phosphoric acid ester residue, X represents hydrogen, hydroxy or hydroxymethyl group, and B represents a purine base residue, and pharmacologically acceptable salts thereof.

Antiviral phosphoric acid esters of oxetanocins

Oxetanocin G which is expectedly useful as an antiviral agent.

Oxetanocin G

This invention relates to oxetanocin-related compounds represented by the following formula (I): ##STR1## [in formula (I), R.sub.1, Y and B have the following meanings: (a) R.sub.1 represents --CH.sub.2 OH or --CH.sub.2 OCO-(alkyl),

Oxetanocin-related compounds and pharmaceutical compositions containing

This invention relates to an antibiotic NK86-0279 of the formula: ##STR1## which exhibits antifungal, antitumor, vascularizations-inhibitory and insecticidal activities.

Antibiotic NK86-0279, process for production of the same and application

This invention relates to an antibiotic NK130119 of the formula: ##STR1## which exhibits antifungal, antitumor, vascularizations-inhibitory and insecticidal activities.

Novel antibiotic NK130119

The present invention provides a novel process for producing oxetanocin G by hydrolysis of alkoxylated 2-amino-oxetanocin A thereby to convert ##STR1## at the 6-position thereof into &gt;C.dbd.O. Oxetanocin G is expectedly useful as an antiviral agent.

Novel process for producing oxetanocin G

This invention relates to a novel antibiotic NK84-0218 of the formula: ##STR1## which exhibits antibacterial, antiviral and antineo-plastic activities and is expected as a pharmaceutical as well as a process for the production of the same.

Novel antibiotic NK84-0218 and process for the production of the same

A pharmaceutical composition for inhibiting Human Immunodeficiency Virus (HIV), which is characterized by comprising a compound represented by the formula (1) ##STR1## or a pharmaceutically acceptable salt thereof as an active ingredient.

Method for inhibiting HIV and an pharmaceutical composition therefor

The present invention relates to a novel compound having hypoxanthine base represented by the following formula: ##STR1## as well as to use of said compound and process for producing said compound. The novel compound of the present invention has an immunosuppressive and antiviral actions and is expected to be useful as a medical drug.

Purine derivative

This invention relates to a novel antibiotic NK84-0218 of the formula: ##STR1## which exhibits antibacterial, antiviral and antineoplastic activities and is expected as a pharmaceutical as well as a process for the production of the same.

Antibiotic derivative of adenine

This invention relates to 2'-deoxy-oxanosine represented by the following formula: ##STR1## and process for the preparation thereof. This new compound exhibits a growth inhibiting action to gram-negative bacteria and has a carcinostatic action.

2'-Deoxyoxanosine

The novel antibiotic, oxanosine, having the structure ##STR1## inhibits the growth of Gram-negative bacteria and has antiviral activity. It is produced by cultivation of an oxanosine-producing microorganism of the genus Streptomyces, preferably Streptomyces capreolus MG265-CF3, ATCC No. 31963.

Antibiotic oxanosine and process for the preparation thereof

The novel antibiotic, oxanosine, having the structure ##STR1## inhibits the growth of Gram-negative bacteria and has antiviral and carcinostatic activity. It is produced by cultivation of an oxanosine-producing microorganism of the genus Streptomyces, preferably Streptomyces capreolus MG265-CF3, ATCC No. 31963.

Growing community of inventors

Tokyo, Japan

Nobuyoshi Shimada